Document resource
Objectives To define a fit-for-purpose clinical outcome assessment for lupus arthritis, with thresholds for entry and improvement, which will form part of the Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE), a novel multi-domain outcome measure for SLE clinical trials.Methods A multi-step consensus process was completed by an international working group comprising ten expert clinicians (including seven adult rheumatologists and three paediatric rheumatologists), one medical statistician and four SLE patients with lived experience of lupus arthritis. First, the domain scope for arthritis in the SLE clinical trial context was defined via structured discussion. Candidate response measures were then nominated via an online survey, and shortlisted for evaluation in a systematic literature review (SLR) focussing on relevant measurement properties and clinical trial utility. Informed by the SLR results, nominal group technique (NGT) was utilised to reach a consensus on a measure for the arthritis domain.Results The arthritis domain was defined with 100% consensus as ‘active inflammatory arthropathy attributed to lupus that impacts the patient and is modifiable by therapy to reduce or control disease activity’, and the scope defined as synovitis, tenosynovitis or other confirmed articular/periarticular inflammation attributed to lupus. Other arthropathies, joint damage and painful pathologies due to lupus that are not musculoskeletal in nature were listed as specific exclusions. A total of 47 measures were nominated for consideration to fit this scope, shortlisted via discussion to 8 (listed in figure 1) which proceeded to evaluation via SLR. The SLR screened 3,729 articles, of which 46 were included. Following review and discussion of the SLR results, 25 unique instruments (either individual measures or a combination of multiple measures) were nominated via survey, and ranked via NGT. The Lupus Arthritis and Musculoskeletal Disease Activity score (LAMDA) was the most highly ranked option. LAMDA incorporates swollen joint count, patient musculoskeletal pain visual analogue scale (VAS), physician musculoskeletal disease activity VAS and erythrocyte sedimentation rate (ESR).Abstract PO:05:137 Figure 1Conclusions Based on formal consensus methodology supported by an SLR, an expert panel including patients reached consensus to use LAMDA to measure disease activity for enrolment and treatment response in the arthritis domain of TRM-SLE.